FindTrial
Sign In

A randomized controlled trial of oral internal compensation ibuprofen for the treatment of PDA in preterm neonates

Developmental pharmacokinetics and pharmacodynamics of chiral ibuprofen associated with the CYP2C8/9 gene polymorphism in premature with PDA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004719
Enrollment
Unknown
Registered
2014-05-22
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature PDA

Interventions

experimental group:The first day the experimental group given 10mg/kg, next 5mg/kg, 5mg/kg third regimen.
Control group:The first day the control group given 10mg/kg, next 5mg/kg, 5mg/kg third regimen.

Sponsors

The Pharmacy Department of Children's Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: preterm newborns,with PDA, girl or boy

Exclusion criteria

Exclusion criteria: Children with severe and serious complications and other test selected candidates

Design outcomes

Primary

MeasureTime frame
plasma concentratio;—

Countries

China

Contacts

Public ContactLi Zhiping

Children's Hospital of Fudan University

zhipinglifudan@yeah.net+86 021 64932030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026